|Articles|October 14, 2019
Quantifying Quality Attributes of AAV Gene Therapy Vectors by SEC-UV-MALS-dRI
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Clears In-Vivo Gene Editing Therapy PBGENE-DMD for Duchenne Trial
2
The Clinical Execution Gap: Why Great Science Often Fails at the Trial Stage
3
Preclinical Study Finds Subcutaneous Nanotrastuzumab Comparable to Herceptin HYLECTA in Minipig Model
4
VectorY Doses First Patient in TDP-43–Targeting ALS Trial
5